3B 级滤泡性淋巴瘤 (G3BFL) 是一种罕见的淋巴瘤，被认为位于低度 FL 和弥漫性大 B 细胞淋巴瘤 (DLBCL) 之间的连续体。定量正电子发射断层扫描 (PET) 指标（例如总代谢肿瘤体积 (TMTV)、总病变糖酵解 (TLG) 和最大标准摄取值 (SUVmax)）在 FL 和 DLBCL 中的预后影响已在 FL 和 DLBCL 中进行了广泛分析，但 G3BFL 数据缺乏。在这里，我们描述了 46 例统一接受 R-CHOP（类似）化疗的 G3BFL 病例的 PET 结果和放射组学特征。使用 MIM 软件进行的中央半自动 PET TMTV、TLG 和 SUVmax 分析与临床结果相关，并与低级别 FL 和 DLBCL 的已发表结果进行比较。在 G3BFL 中，治疗结束时的完全代谢反应与改善的无进展生存期（PFS；p = 0.002）和总生存期（OS；p = 0.04）相关。 G3BFL 中位 TLG (1455) 和 SUVmax (16.50) 位于已公布的低级 FL 值（TLG：1112，SUVmax：11.3）和 DLBCL（TLG：3004，SUVmax：24.35）之间。 TMTV (>350cm3) 与生存率之间没有关联（PFS：p= 0.24；OS：p= 0.40）。高 SUVmax (>19.2) 和 TLG (>2760) 均导致较差的 PFS，但不影响 OS（PFS：SUVmax p = 0.004；TLG p = 0.05）。这些数据支持在基线和 G3BFL 治疗反应中常规纳入 PET 放射组学。© 2024 英国血液学会和 John Wiley

Grade 3B follicular lymphoma (G3BFL) is a rare lymphoma thought to sit on a continuum between low-grade FL and diffuse large B-cell lymphoma (DLBCL). The prognostic impact of quantitative positron emission tomography (PET) metrics such as total metabolic tumour volume (TMTV), total lesion glycolysis (TLG), and maximum standard uptake value (SUVmax) have been extensively analysed in FL and DLBCL, but G3BFL data are lacking. Here, we describe PET outcomes and radiomic characteristics in 46 G3BFL cases uniformly treated with R-CHOP (like) chemotherapy. Central semi-automated PET TMTV, TLG, and SUVmax analyses, using MIM software, were correlated with clinical outcomes and compared with published results in low-grade FL and DLBCL. In G3BFL, the end-of-treatment complete metabolic response was associated with improved progression-free survival (PFS; p = 0.002) and overall survival (OS; p = 0.04). G3BFL median TLG (1455) and SUVmax (16.50) sit between published values for low-grade FL (TLG: 1112, SUVmax: 11.3) and DLBCL (TLG: 3004, SUVmax: 24.35). No association between TMTV (>350 cm3) and survival was seen (PFS: p = 0.24; OS: p = 0.40). High SUVmax (>19.2) and TLG (>2760) both conferred inferior PFS but not OS (PFS: SUVmax p = 0.004; TLG p = 0.05). These data support the routine incorporation of PET radiomics at baseline and treatment response for G3BFL.© 2024 British Society for Haematology and John Wiley & Sons Ltd.